College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Hanmi Research Center, Hanmi Pharm. Co. Ltd., Gyeonggi-Do, Republic of Korea.
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1928-1936. doi: 10.1080/14756366.2020.1833876.
The importance of transforming growth factor beta-activated kinase 1 (TAK1) to cell survival has been demonstrated in many studies. TAK1 regulates signalling cascades, the NF-κB pathway and the mitogen-activated protein kinase (MAPK) pathway. TAK1 inhibitors can induce the apoptosis of cancerous cells, and irreversible inhibitors such as (5Z)-7-oxozeaenol are highly potent. However, they can react non-specifically with cysteine residues in proteins, which may have serious adverse effects. Reversible covalent inhibitors have been suggested as alternatives. We synthesised imidazopyridine derivatives as novel TAK1 inhibitors, which have 2-cyanoacrylamide moiety that can form reversible covalent bonding. A derivative with 2-cyano-3-(6-methylpyridin-2-yl)acrylamide () exhibited potent TAK1 inhibitory activity with an IC of 27 nM. It showed a reversible reaction with β-mercaptoethanol, which supports its potential as a reversible covalent inhibitor.
转化生长因子-β激活激酶 1(TAK1)在许多研究中被证明对细胞存活很重要。TAK1 调节信号级联、NF-κB 途径和丝裂原活化蛋白激酶(MAPK)途径。TAK1 抑制剂可诱导癌细胞凋亡,不可逆抑制剂如(5Z)-7-氧杂豆醇具有很高的活性。然而,它们可能会与蛋白质中的半胱氨酸残基发生非特异性反应,从而产生严重的副作用。因此,人们提出了可逆共价抑制剂作为替代物。我们合成了作为新型 TAK1 抑制剂的咪唑并吡啶衍生物,其具有 2-氰基丙烯酰胺部分,可以形成可逆的共价键。具有 2-氰基-3-(6-甲基吡啶-2-基)丙烯酰胺()的衍生物具有 27 nM 的 TAK1 抑制活性,与β-巯基乙醇发生可逆反应,这支持了其作为可逆共价抑制剂的潜力。